These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 11298060)
21. Safety and tolerability of extended-release oxybutynin once daily in urinary incontinence: combined results from two phase 4 controlled clinical trials. Armstrong RB; Dmochowski RR; Sand PK; Macdiarmid S Int Urol Nephrol; 2007; 39(4):1069-77. PubMed ID: 17333521 [TBL] [Abstract][Full Text] [Related]
22. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder. Kreder K; Mayne C; Jonas U Eur Urol; 2002 Jun; 41(6):588-95. PubMed ID: 12074774 [TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation. The International Study Group. Jonas U; Höfner K; Madersbacher H; Holmdahl TH World J Urol; 1997; 15(2):144-51. PubMed ID: 9144906 [TBL] [Abstract][Full Text] [Related]
24. A multicenter, prospective, open-label study of tolterodine extended-release 4 mg for overactive bladder: the speed of onset of therapeutic assessment trial (STAT). Siami P; Seidman LS; Lama D Clin Ther; 2002 Apr; 24(4):616-28. PubMed ID: 12017406 [TBL] [Abstract][Full Text] [Related]
25. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study. Chancellor MB; Zinner N; Whitmore K; Kobashi K; Snyder JA; Siami P; Karram M; Laramée C; Capo' JP; Seifeldin R; Forero-Schwanhaeuser S; Nandy I Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833 [TBL] [Abstract][Full Text] [Related]
26. Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine. Freeman R; Hill S; Millard R; Slack M; Sutherst J; Obstet Gynecol; 2003 Sep; 102(3):605-11. PubMed ID: 12962951 [TBL] [Abstract][Full Text] [Related]
27. Retrospective analysis of efficacy and tolerability of tolterodine in children with overactive bladder. Raes A; Hoebeke P; Segaert I; Van Laecke E; Dehoorne J; Vande Walle J Eur Urol; 2004 Feb; 45(2):240-4. PubMed ID: 14734013 [TBL] [Abstract][Full Text] [Related]
28. Advances in medical management of overactive bladder. Richelson E; Elliott DS Mayo Clin Proc; 2003 Jun; 78(6):681-3. PubMed ID: 12934775 [No Abstract] [Full Text] [Related]
29. Investigation of the clinical efficacy and safety of pregabalin alone or combined with tolterodine in female subjects with idiopathic overactive bladder. Marencak J; Cossons NH; Darekar A; Mills IW Neurourol Urodyn; 2011 Jan; 30(1):75-82. PubMed ID: 20886571 [TBL] [Abstract][Full Text] [Related]
30. Tolterodine extended release in the treatment of male OAB/storage LUTS: a systematic review. Gacci M; Novara G; De Nunzio C; Tubaro A; Schiavina R; Brunocilla E; Sebastianelli A; Salvi M; Oelke M; Gravas S; Carini M; Serni S BMC Urol; 2014 Oct; 14():84. PubMed ID: 25348235 [TBL] [Abstract][Full Text] [Related]
31. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Abrams P; Freeman R; Anderström C; Mattiasson A Br J Urol; 1998 Jun; 81(6):801-10. PubMed ID: 9666761 [TBL] [Abstract][Full Text] [Related]
32. Comparison of fesoterodine and tolterodine in patients with overactive bladder. Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298 [TBL] [Abstract][Full Text] [Related]
33. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder in Japanese patients. Takei M; Homma Y; Int J Urol; 2005 May; 12(5):456-64. PubMed ID: 15948744 [TBL] [Abstract][Full Text] [Related]
34. Safety and tolerability of tolterodine for the treatment of overactive bladder in adults. Roberts RG; Garely AD; Bavendam T Am J Manag Care; 2005 Jul; 11(4 Suppl):S158-62. PubMed ID: 16161389 [TBL] [Abstract][Full Text] [Related]
36. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Appell RA Urology; 1997 Dec; 50(6A Suppl):90-6; discussion 97-9. PubMed ID: 9426760 [TBL] [Abstract][Full Text] [Related]
37. Use of tolterodine in children with neurogenic detrusor overactivity: relationship between dose and urodynamic response. Ellsworth PI; Borgstein NG; Nijman RJ; Reddy PP J Urol; 2005 Oct; 174(4 Pt 2):1647-51; discussion 1651. PubMed ID: 16148673 [TBL] [Abstract][Full Text] [Related]
38. Multiple dose pharmacokinetics of a new once daily extended release tolterodine formulation versus immediate release tolterodine. Olsson B; Szamosi J Clin Pharmacokinet; 2001; 40(3):227-35. PubMed ID: 11327200 [TBL] [Abstract][Full Text] [Related]
39. Tolterodine: a clinical review. Crandall C J Womens Health Gend Based Med; 2001 Oct; 10(8):735-43. PubMed ID: 11703885 [TBL] [Abstract][Full Text] [Related]
40. A new once-daily formulation of tolterodine provides superior efficacy and is well tolerated in women with overactive bladder. Swift S; Garely A; Dimpfl T; Payne C; Int Urogynecol J Pelvic Floor Dysfunct; 2003 Feb; 14(1):50-4; discussion 54-5. PubMed ID: 12601517 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]